Big Pharma aces brand valuations for 2019, with Roche once again leading the way

Roche
Roche led global pharma brand valuations for the second year in a row in Brand Finance's study, thanks to ongoing investment in drug development. (Roche)

Pharma brand valuation is on the rise. That’s according to Brand Finance’s annual study, which calculated an 11.5% increase in U.S. pharma companies' brand value and a similar 11.2% increase for global brands.

Roche retained the top spot in the brand ranking, followed by Bayer and Pfizer in the second and third spots, switching places from last year. All three increased their brand valuations over 2018's showing, with Roche gaining 7.8%, Bayer jumping by 11.5% and Pfizer leaping 16.5%. The Brand Finance report attributed Roche's growth to "its continued investment in world-leading drug development."

It was Merck that made the biggest jump in the study, though, with an increase of 29% and a move into the No. 5 spot. Novartis, meanwhile, was the only pharma brand to see a decrease in value, down 6.1%, which Brand Finance consultant Hugo Hensley attributed to its announcement that it would spin off Alcon, a well-known consumer product division that added brand impact.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Overall, it was a strong year for pharma brands. In fact, the total industry increase in brand valuation came in spite of a decrease of 3% in total enterprise value of their businesses, Hensley said in an email interview. That means pharma companies made solid improvement in measures of brand strength, financial forecasts and market conditions even as their stock market values stagnated.

RELATED: Pharma's most-valuable brands? J&J, Pfizer and Merck. Valeant, not so much

Pharma brands from the U.S. landed in five of the top 10 spots in the ranking and comprised 46% of the total brand value in the study. Brand Finance evaluates all public pharma companies with valuations of $1 billion or more.

The U.S.-specific growth “was mostly due to strong business growth and M&A activity. The big brands, many of which are U.S.-based, are quickly attempting to improve their pipelines by acquiring promising smaller companies,” Hensley said.

While that worked to their brand value advantage this year, he cautioned Big Pharma to remain aware of the potential that an acquisitive strategy has to stifle the perception of innovation, and to carefully consider the pros and cons of each of the brands acquired.

RELATED: Can cancer charity efforts from Roche, Bristol-Myers Squibb, AbbVie and more boost pharma's reputation?

Hensley had more advice to pharma companies looking to bump up brand valuation in the coming year, too. He suggested focusing on the most actionable areas inside Brand Finance's Brand Strength Index, which include brand investment in marketing and brand performance.

“Effective brand investment is the only way to enhance the brand value consistently over time, as the effects feed through into stakeholder equity and business performance,” he said.

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.